---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132890"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:48:53.654834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports positive Phase 2b topline results for Haduvio in IPF chronic cough

## Summary
- Primary endpoint met: 60.2% reduction in 24-hour cough frequency at 108 mg BID (p<0.0001) vs 16.9% placebo.
- Statistically significant improvements on cough-severity NRS and E-RS:IPF Cough Subscale at 108 mg and 54 mg BID.
- Discontinuation due to AEs similar between Haduvio (5.6%) and placebo (5.0%); safety profile consistent with prior trials.
- Expects end-of-Phase 2 FDA meeting in H2 2025; plans Phase 2b trial in refractory chronic cough starting H1 2026.
- Also plans to initiate clinical trial of Haduvio for non-IPF interstitial lung disease cough in H2 2025.

## SEC filing metadata
- accession: 0001193125-25-132890
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312525132890/0001193125-25-132890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312525132890/d949267d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132890
- JSON: https://secwatch.observer/filing/0001193125-25-132890.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.